Overview
- In mid-June 2026 Ahold Delhaize USA agreed to pay $40 million to resolve allegations that some supermarket pharmacies reported inflated 'usual and customary' prescription prices when billing Medicare Part D, Medicaid and TRICARE.
- Federal authorities say the company failed to report lower prices from customer savings programs as the pharmacies' usual rates, which pushed government reimbursements higher under the payment formulas those programs use.
- The Justice Department will receive about $32.9 million of the settlement, participating state Medicaid programs will get the remainder, and whistleblower pharmacist Lawrence LaBenne will receive more than $6 million from the federal share.
- Ahold Delhaize said it admitted no wrongdoing, cooperated with the inquiry, and noted the settlement concerns billing and reporting practices rather than the prices consumers paid at store checkouts.
- The case follows broader scrutiny of pharmacy reporting practices and could prompt closer oversight of how retail pharmacies report discount-program prices for government reimbursement formulas.